文献速递银屑病与炎症性皮肤病

甲氨蝶呤给药途径对银屑病药物生存的影响:PSOBIOTEQ研究结果

Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-09-30

基于法国Psobioteq注册队列,纳入406例首次接受甲氨蝶呤单药治疗的中重度银屑病患者,58.1%口服、41.9%皮下注射。调整后药物生存率无显著差异(p=0.15),但皮下注射因无效停药的风险更低、因不耐受停药的风险更高。

要点

  • 甲氨蝶呤口服与皮下注射的总体药物生存无显著差异。
  • 皮下注射因无效停药风险更低,但因不耐受停药风险更高。
  • 给药途径选择应个体化,权衡疗效与不良反应。

核心结论

  • 甲氨蝶呤总体药物生存不因给药途径而显著不同,但皮下注射因无效停药风险更低、因不耐受停药风险更高。

研究设计与样本

  • 基于Psobioteq注册的前瞻性队列研究,纳入2012年7月至2023年1月首次接受甲氨蝶呤单药治疗的斑块状、红皮病型或点滴状银屑病患者,共406例。

主要发现

  • 406例患者中58.1%口服甲氨蝶呤,41.9%皮下注射。
  • 开始甲氨蝶呤时中位PASI评分为11,67.3%患者DLQI≥6。
  • 调整后药物生存率按给药途径无统计学差异(p=0.15)。

临床怎么用

  • 临床选择甲氨蝶呤给药途径应个体化,皮下注射可能疗效更好但不良反应风险更高,口服方便但部分患者疗效可能较差。

局限性

  • 患者数量有限可能导致把握度不足。
  • 观察性数据无法排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on the impact of the route of administration of methotrexate (MTX) on drug survival in psoriasis. OBJECTIVE: To evaluate the impact of the initial route of administration of MTX (monotherapy) on drug survival in patients with moderate to severe skin psoriasis. MATERIALS AND METHODS: A prospective cohort study based on the Psobioteq registry, included from July 2012 to January 2023, patients with plaque, erythrodermic or guttate psoriasis, naive to MTX, biologics and apremilast, who initiated MTX monotherapy. Factors associated with drug survival were identified using Kaplan-Meier curves and Cox regression analyses. RESULTS: In total, 406 patients were included, 58.1% received MTX per os (MTX-PO) and 41.9% subcutaneously (MTX-SC). At MTX initiation, the median PASI score was 11, and 67.3% had DLQI ≥6. Adjusted drug survival did not statistically differ according to the route of administration (p = 0.15). LIMITATIONS: Limited number of patients leading to a potential lack of power. Residual confounding cannot be waived due to the observational nature of the data. CONCLUSIONS: Overall MTX survival did not significantly differ according to the route of administration. However, with MTX-SC, the hazard of discontinuation for ineffectiveness was lower and of discontinuation for intolerance was higher than with MTX-PO. Psoriasis is a common, long‐term skin disease that causes red, scaly patches and can greatly affect quality of life. Many patients with moderate‐to‐severe psoriasis need systemic treatments, such as methotrexate (MTX), which is widely used because it is effective and affordable. This study was carried out in France, using data from the national Psobioteq registry, which follows patients with psoriasis receiving systemic treatments. We wanted to know whether the way MTX is given—by mouth (oral tablets, MTX‐PO) or by injection under the skin (subcutaneous, MTX‐SC)—influences how long patients stay on treatment and the reasons for stopping it. We followed 406 patients with moderate‐to‐severe psoriasis who started MTX as their first systemic treatment between 2012 and 2022. About 58% received MTX‐PO and 42% MTX‐SC. We recorded how long patients continued the treatment and why they stopped. Overall, the length of time patients continued MTX did not differ much between the two groups. However: Patients treated with MTX‐SC were less likely to stop because the treatment was not effective.Patients treated with MTX‐SC were more likely to stop because of side effects or intolerance. Both ways of giving MTX are useful options for psoriasis. MTX‐SC may be more effective but can cause more side effects, while MTX‐PO is easier to take but may work less well for some patients. These findings suggest that the choice of treatment route should be personalized, balancing expected benefits and possible side effects.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Paris C, Curmin R, Gouillon L, et al. Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2025. PMID: 41024667. doi:10.1111/jdv.70044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。